The Polish competent authorities published their report on the SCoPAFF Legislation meeting of 30-31 March 2022.
SCoPAFF Legislation report 1-2 December 2021 published
On 24.03.2022 the summary report for the 01-02-12.2021 SCoPAFF Legislation meeting was published on the DG SANTE website.
Agenda SCoPAFF Legislation 30-31 March published
On 14.03.2022 the agenda for the SCoPAFF Legislation meeting of 30-31.03.2022 was published on the DG SANTE website.
SCoPAFF Legislation agenda 1-2 December
DG SANTE published the agenda for the SCoPAFF Legislation meeting of 1-2 December 2021.
Agenda SCoPAFF Legislation October 2021 published
On 05.10.2021 the agenda for the upcoming SCoPAFF Legislation meeting of 21-22.10.2021 was published.
EFSA conclusion benthiavalicarb
On 27.09.2021 EFSA published its conclusion on the peer review of benthiavalicarb.
SCoPAFF Legislation agenda 19-20 May 2021
The agenda for the SCoPAFF Legislation meeting of 19-20.05.2021 is published on the SANTE website.
SCoPAFF Legislation (Jan.2021) report published
DG SANTE published the summary report of the 25-26 January meeting.
Agenda SCoPAFF Legislation 24-25 March published
The agenda for the upcoming SCoPAFF Legislation meeting was published on the Commission website.
SCoPAFF Legislation report 22-23.10.2020
On 04.03.2021 DG SANTE published the short report on the SCoPAFF Legislation meeting of 22-23.10.2020.
EFSA consultation metiram
On 01.03.2021 EFSA opened a public consultation on the RAR for metiram, as well as on a draft Art. 4.7 report and its underlying documents.
SCoPAFF Legislation agenda January 2021 published
On 06.01.2021, the agenda for the upcoming SCoPAFF Legislation meeting of 25-26.01.2021 was published.
Agenda SCoPAFF Legislation 22-23 October 2020
The agenda for the SCoPAFF Legislation meeting of 22-23.10.2020 was published on 06.10.2020
benthiavalicarb ED & Art. 4.7 consultation
EFSA opened on 27.07.2020 a public consultation on benthiavalicarb, regarding the assessments following the stop-the-clock for Endocrine Disruption assessment.
EFSA report on bromoxynil negligible exposure
On 13.12.2018 EFSA published its conclusions on the peer review of the risk assessment of bromoxynil in the light of negligible exposure (report 5490).
Feedback PAFF meeting 23-24 October 2018
First feedback was received from the PAFF Meeting of 23-24 October 2018.
EFSA reports on flumioxazin negligible exposure
On 08.10.2018 EFSA published its conclusions on the peer review of the risk assessment of flumioxazin in the light of negligible exposure (report 5415).